Enzon to Release Second Quarter 2010 Earnings on Tuesday, August 3, 2010; Conference Call and Webcast to Follow
BRIDGEWATER, N.J.--([ BUSINESS WIRE ])--Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended June 30, 2010, on Tuesday, August 3, 2010 at 4:00 pm Eastern Time (ET). The release will be followed by a live conference call, which will begin at 5:00 pm Eastern Time (ET) on Tuesday, August 3, 2010.
All interested parties may access the call by using the following information:
Domestic Dial-In Number: | (877) 561-2748 |
International Dial-In Number: | (720) 545-0044 |
Access Code: | Enzon |
The call will also be available via live audio webcast at the following site: [ http://investor.enzon.com/eventdetail.cfm?eventid=84459 ]. Listeners should go to the website at least fifteen minutes before this event to download and install any necessary audio software. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will also be available following the call. The rebroadcast will begin on Tuesday, August, 3, 2010 at approximately 8:00 pm Eastern Time (ET) and end on Tuesday, August 10, 2010 at approximately 11:59pm Eastern Time (ET). It may be accessed using the following information:
Domestic Dial-In Number: | (800) 642-1687 |
International Dial-In Number: | (706) 645-9291 |
Conference I.D.: | 90977127 |
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of innovative medicines for patients with cancer. Enzona™s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform, Customized Linker technologya" and mRNA antagonists using the Locked Nucleic Acida" (LNA) technology. Enzon receives a royalty revenue stream from licensing partnerships for other products developed using the proprietary PEGylation technology. Further information about Enzon and this press release can be found on the Companya™s web site at [ www.enzon.com ].